Consequently, the mechanisms by which KLC2 mutations enhance STAT3 activation in CML cells or whether this activation relies on the KLC2/SMAD2/3 axis remain unclear, and we acknowledge these limitations. This evidence concerns the gene SMAD2 and chronic myelogenous leukemia, BCR-ABL1 positive.